NOVO-CEFUROXIME TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Osta se nyt

Lataa Valmisteyhteenveto (SPC)
22-04-2008

Aktiivinen ainesosa:

CEFUROXIME (CEFUROXIME AXETIL)

Saatavilla:

NOVOPHARM LIMITED

ATC-koodi:

J01DC02

INN (Kansainvälinen yleisnimi):

CEFUROXIME

Annos:

125MG

Lääkemuoto:

TABLET

Koostumus:

CEFUROXIME (CEFUROXIME AXETIL) 125MG

Antoreitti:

ORAL

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

SECOND GENERATION CEPHALOSPORINS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0122448006; AHFS:

Valtuutuksen tilan:

CANCELLED PRE MARKET

Valtuutus päivämäärä:

2015-10-16

Valmisteyhteenveto

                                PRODUCT MONOGRAPH
PR
NOVO–CEFUROXIME
(Cefuroxime Axetil Tablets, USP)
125 mg, 250 mg and 500 mg cefuroxime/tablet
Antibiotic
Control Number: 031000
Novopharm Limited
Date of Preparation:
Toronto, Canada
April 03, 2008
PR
NOVO–CEFUROXIME
(Cefuroxime Axetil Tablets, USP)
125 mg, 250 mg and 500 mg cefuroxime/tablet
Antibiotic
ACTIONS AND CLINICAL PHARMACOLOGY
Cefuroxime axetil is an orally active prodrug of cefuroxime. After
oral administration, NOVO-
CEFUROXIME (cefuroxime axetil) is absorbed from the gastrointestinal
tract and rapidly
hydrolyzed by nonspecific esterases in the intestinal mucosa and blood
to release cefuroxime
into the blood stream. Conversion to cefuroxime, the microbiologically
active form, occurs
rapidly. The inherent properties of cefuroxime are unaltered after its
administration as
cefuroxime axetil. Cefuroxime exerts its bactericidal effect by
binding to an enzyme or
enzymes referred to as penicillin-binding proteins (PBPs) involved in
bacterial cell wall
synthesis.
This binding results in inhibition of bacterial cell wall synthesis
and subsequent cell death.
Specifically, cefuroxime shows high affinity for PBP 3, a primary
target for cefuroxime in
gram-negative organisms such as
_E. coli._
A comparative, two-way, single-dose, fasting bioavailability study was
performed on two 250
mg cefuroxime axetil products, NOVO-CEFUROXIME 250 mg tablets and
Ceftin
®
250 mg
tablets. The pharmacokinetic data calculated for cefuroxime axetil in
the NOVO-
CEFUROXIME and Ceftin
®
tablet formulations is tabulated in Table 1.
Table 1
Geometric Mean
Arithmetic Mean (C.V.)
Novo-Cefuroxime
(2 x 250 mg)
Ceftin
®**
(2 x 250 mg)
Percentage of Ceftin
®
AUC
T
(ng•hr/mL)
15.65
16.33 (28)
16.44
17.48 (36)
95
AUC
I
(ng•hr/mL)
16.36
16.97 (27)
17.12
18.16 (35)
96
C
max
(ng/mL)
5.39
5.63 (28)
5.50
5.76 (32)
98
T
max
*
(hr)
1.33 (0.25)
1.74 (0.97)
---
T
1/2
*
(hr)
1.26 (0.20)
1.32 (0.19)
---
*For the
T
max
and
T
1/2
parameters these are the arithmetic means (standard deviation).
**Ceftin® manufactured by Glaxo C
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia